Medicine

Medicine Recent News

Moderna Hires Harvard Stem Cell Researcher Jonathan Hoggatt as Director of Hematology: What You Need to Know
Moderna, Inc.
How Will Psychedelics Become Medicine? A Scientific Review Of The Drug Development Pathway
This article was originally published on Microdose Psychedelic Insights and appears here with permission.
Cannabis Doesn't Cause Cognitive Decline, Twin Study Finds
This article was originally published on The Cannigma, and appears here with permission.
Regulators Approve GW Pharmaceuticals' Cannabis-based Epidyolex In Australia
Epidyolex, the first FDA approved CBD medicine for severe epilepsy in children, received Australian Therapeutic Goods Administration approval.
Compass IPO: A 'Clear Bellwether For Growing Psychedelic Medicine Industry'
On Friday, UK-based mental health care company Compass Pathways (NASDAQ: CMPS) announced it has begun trading on NASDAQ under the symbol CMPS. This is the first time a psychedelics company is listed on a major U.S. Stock Exchange.
Afya IPO: What You Need To Know
3 Pharma Companies Investing In Cannabis-Related Treatments
3 Pharma Companies That Could Deliver Breakthroughs In 'Plantibody' Technology
Why Investors Should Closely Watch Celgene
3 Reasons To Buy Merck For The Long Term
Pharmaceutical ETFs Are Health Care Sector Standouts
2 Biotech Stocks With Massive Increases In Short Interest
Alzheimer's Rates Falling, But Pharma's Search For A Cure Yields No Results
5-Star Biotech Stock Watch: Aegerion Pharmaceuticals
Walgreen Co. Or CVS Caremark: Which Would You Rather?
Advances In HIV, Hep C Treatments Could Spark Renewed Interest In Biotech Stocks
Biogen Raises Full-Year Earnings, But Is That The Entire Picture?
Biotech ETFs Come Back Down To Earth
Procter & Gamble vs. Johnson & Johnson: Which is the Better Bet?
GlaxoSmithKline Rocked By China Bribery Scandal
Food Allergy Bill Offers Financial Incentives for States That Have Emergency Meds at Schools
Pfizer Partnering With Zacharon To Develop Rare-Disease Drugs
Overview of regenerative medicine sector together with its opportunities

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2024 Benzinga | All Rights Reserved